Abstract |
N-Methylformamide (N-MF) belongs to a class of polar-planar compounds which induce cellular differentiation. Preclinical antitumor activity was demonstrated against human mammary, colon, and lung tumor xenografts and L1210 and P388 murine leukemias. This phase I study used a single bolus infusion of N-MF given weekly X 3 doses every 6 weeks. Thirty-five patients were treated with N-MF at doses which ranged from 125 to 3125 mg/m2/week. The dose-limiting toxic effects included nausea and vomiting, anorexia, malaise, and liver function abnormalities. No myelosuppression was seen. The recommended dose for phase II trials of N-MF with this schedule is to initiate therapy at 2000 mg/m2 weekly X 3 and escalate to 2500 mg/m2 if the initial dose was well tolerated.
|
Authors | D S Ettinger, D W Orr, A P Rice, R C Donehower |
Journal | Cancer treatment reports
(Cancer Treat Rep)
Vol. 69
Issue 5
Pg. 489-93
(May 1985)
ISSN: 0361-5960 [Print] United States |
PMID | 4005871
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Formamides
- methylformamide
|
Topics |
- Adult
- Aged
- Anorexia
(chemically induced)
- Antineoplastic Agents
(therapeutic use)
- Drug Evaluation
- Female
- Formamides
(adverse effects, therapeutic use)
- Humans
- Liver
(drug effects)
- Male
- Middle Aged
- Nausea
(chemically induced)
- Neoplasms
(drug therapy)
- Vomiting
(chemically induced)
|